IFI35 and primary cutaneous T-cell non-Hodgkin lymphoma: With cutaneous T-cell lymphoma, IFI35 was shown to be significantly down-regulated in the malignant cell population [16], which is consistent with our finding that IFI35 may suppress tumor growth.